References
Agata M, Tanaka M, Nakajima A, Fujii A. Kuboyama N. et al. Ocular penetration of topical diclofenac sodium, a non-steroidal anti-inflammatory drug, in rabbit eye. Nippon Ganka Gakkai Zasshi 88: 991–996. 1984
Ahmed I, Gokhale RD, Shah MV, Patton TF. Physicochemical determinants of drug diffusion across the conjunctiva, sciera, and cornea. Journal of Pharmaceutical Sciences 76: 583–586, 1987
Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Investigative Ophthalmology and Visual Science 26: 584–587. 1985
Anderson JA, Chen CC, Vita JB, Shackleton M. Disposition of topical flurbiprofen in normal and aphakic rabbit eyes. Archives of Ophthalmology 100:642–645. 1982
Athanasios T, Gartaganis SP, Chrysanthopoulos CJ, Beerman D, Papachristou C. et al. Aqueous humor penetration of ciprofloxacin in the human eye. Archives of Ophthalmology 106: 404–405. 1988
Barza M, Kane A, Baum JL. Intraocular levels of cefamandole compared with cefazolin after subconjunctival injection in rabbits. Investigative Ophthalmology and Visual Science 18: 250–255, 1979
Barza M. McCue. M. Pharmacokinetics of aztreonam in rabbit eyes. Antimicrobial Agents and Chemotherapy 24: 468–473, 1983
Becker B. Decrease in the intraocular pressure in man by a carbonic anhydrase inhibitor. Diamoz. American Journal of Ophthalmology 37: 13–15, 1954
Bito LZ, Baroody RA. The ocular pharmacokinetics of eicosanoids and their derivatives. I. Comparison of ocular Eicosanoid penetration and distribution following the topical application of PGF2alpha. PGF2alpha-l-methyl ester, and PGF2alpha-l-isopropyl ester. Experimental Eye Research 44: 217–226, 1987
Bodor N. Soft drugs: principles and methods for the design of safe drugs. Medicinal Research Reviews 4: 449–469, 1984
Bourne WM, Nagataki S, Brubaker RF. The permeability of the corneal endothelium to fluorescein in the normal human eye. Current Eye Research 3: 509–513, 1984
Brown C, Hanna C. Use of dilute drug solutions for routine cycloplegia and mydriasis. American Journal of Ophthalmology 86: 820–824, 1978
Brown RH, Wood TS, Lynch MG. Schoenwald RD, Chien DS, et al. Improving the therapeutic index of topical phenylephrine by reducing drop volume. Ophthalmology 94: 847–850, 1987
Bundgaard H. Flach E, Larsen C, Mosher GL, Mikkelson TJ. Pilocarpine acid esters as novel sequentially labile pilocarpine prodrugs for improved ocular delivery. Journal of Medicinal Chemistry 28: 979–981, 1985
Burstein NL, Anderson JA. Corneal penetration and ocular bio-availability of drugs. Journal of Ocular Pharmacology 1: 309–326, 1985
Cable MK. Hendrickson RO, Hanna C. Evaluation of drugs in ointment for mydriasis and cycloplegia. Archives of Ophthalmology 96: 84–86, 1978
Camber O, Edman P, Olsson LI. Permeability of prostaglandin F2alpha and prostaglandin F2alpha esters across cornea in vitro. International Journal of Pharmaceuticals 29: 259–266, 1986
Chang SC, Bundgaard H, Buur A, Lee VHL. Improved corneal penetration of timolol by prodrugs as a means to reduce systemic drug load. Investigative Ophthalmology and Visual Science 28: 487–491, 1987
Chiang CH, Huang HS, Schoenwald RD. Corneal permeability of adrenergic agents potentially useful in glaucoma. Journal of the Taiwan Pharmaceutical Association 38: 67–84, 1986.
Chiang CH, Schoenwald RD. Ocular pharmacokinetic models of clonidine-3H hydrochloride. Journal of Pharmacokinetics and Biopharmaceutics 14: 175–211. 1986
Chien DS, Schoenwald RD. Improving the ocular absorption of phenylephrine. Biopharmaceutics and Drug Disposition 7: 453–462, 1986
Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. Journal of Pharmaceutical Sciences 63: 333–338, 1974
Chrai SS, Patton TF, Mehta A, Robinson JR. Lacrimal and instilled fluid dynamics in rabbit eyes. Journal of Pharmaceutical Sciences 62: 1112–1121, 1973
Cole DF. Ocular fluids. In Davson (Ed.) The eye, 3rd ed.. pp. 269–390, Academic Press, Inc., Orlando, 1984
Conrad JM. Robinson JR. Aqueous chamber drug distribution volume measurement in rabbits. Journal of Pharmaceutical Sciences 66: 219–224. 1977
Conroy CW. Schwam H. Maren TH. The nonenzymatic displacement of the sulfamoyl group from different classes of aromatic compounds by glutathione and cysteine. Drug Metabolism and Disposition 12: 614–618. 1984
Cotlier E, Sharma YR, Niven T, Brescia M. Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation. American Journal of Medicine 74: 83–90. 1983
De Santis L, Sallee V, Barnes G, Schoenwald R, Barfknecht C, et al. The effect of topically applied analogs of carbonic anhy-drase inhibitor, ethoxzolamide, on intraocular pressure in alert laser-induced ocular hypertensive cynomologous monkeys. Investigative Ophthalmology and Visual Science (Suppl. 27): 179. 1986
Doane MG, Jensen AD, Dohlman CH, Penetration routes of topically applied eye medications. American Journal of Ophthalmology 85: 383–386. 1978
Duffell MW. Ing IS, Segarra TM, Dixson JA, Barfknecht CF. et al. N-substituted sulfonamide carbonic anhydrase inhibitors with topical effects on intraocular pressure. Journal of Medicinal Chemistry 29: 1488–1494. 1986
Duzman E, Anderson J, Vita JB, Lue JC, Chen CC. et al. Topically applied oxymetazoline: ocular vasoconstrictive activity, pharmacokinetics, and metabolism. Archives of Ophthalmology 101: 1122–1127, 1983
Edelhauser HF, Maren TH. Permeability of human cornea and sciera to sulfonamide carbonic anhydrase inhibitors. Archives of Ophthalmology 106: 1110–1114, 1988
Eller MG, Schoenwald RD, Dixson JA, Segarra T, Barfknecht CF. Topical carbonic anhydrase inhibitors III: optimization model for corneal penetration of ethoxzolamide analogues. Journal of Pharmaceutical Sciences 74: 155–160, 1985a
Eller MG, Schoenwald RD, Dixson JA, Segarra T, Bartknecht CF. Topical carbonic anhydrase inhibitors IV: relationships between excised corneal permeability and pharmacokinetic factors. Journal of Pharmaceutical Sciences 74: 525–529, 1985b
Fantes FE, Heuer DK, Parrish II RK, Sossi N, Gressel MG. Topical fluorouracil: pharmacokinetics in normal rabbit eyes. Archives of Ophthalmology 103: 953–955, 1985
Francoeur ML, Sitek SJ, Costello B. Patton TF. Kinetic disposition and distribution of timolol in the rabbit: a physiologically based ocular model. International Journal of Pharmaceutics 25: 275–292, 1985
Fraunfelder FT. Meyer SM. Systemic side effects from ophthalmic timolol and their prevention. Journal of Ocular Pharmacology 3: 177–184. 1987
Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed.. pp. 34–35. Marcel Dekker Inc., New York. 1982
Grass GM, Robinson JR, Mechanisms of corneal drug penetration I: in vivo and in vitro kinetics. Journal of Pharmaceutical Sciences 77: 3–14. 1988
Grove J, Gautheron P, Plazonnet B, Sugrue M. Ocular disposition studies of the topical carbonic anhydrase inhibitors L-643,799 and L-650.719 and related alkyl prodrugs. Journal of Ocular Pharmacology 4: 279–290. 1988
Gudauskas G, Kumi C, Dedhar C, Bussanich N, Rootman J. Ocular pharmacokinetics of subconjunctivally versus intravenously administered 6-mercaplopurine. Canadian Journal of Ophthalmology 20: 110–113. 1985
Havener WH. Ocular Pharmacology. 5th ed.. pp. 379–390. C.V. Mosby Co., St Louis, 1983
Himmelstein KJ, Guvenir I, Patton TF. Preliminary pharmacokinetic model of pilocarpine uptake and distribution in the eye. Journal of Pharmaceutical Sciences 67: 603–606. 1978
Hitoshi S, Bundgaard H, Lee VHL. Design of prodrugs to selectively reduce timolol absorption on the basis of the differential lipophilic characteristics of the cornea and the conjunctiva. In vestigative Ophthalmology and Visual Science (Suppl. 30): 25. 1989
Huang HS, Schoenwald RD, Lach JL. Corneal penetration behavior of beta-blocking agents II: assessment of barrier contributions. Journal of Pharmaceutical Sciences 72: 1272–1279, 1983
Hui HW, Zeleznick L, Robinson JR. Ocular disposition of topically applied histamine, cimetidine and pyrilamine in the albino rabbit. Current Eye Research 3: 321–330. 1984
Huupponen R, Kaila T, Salminen L, Urtti A. The pharmacokinetics of ocularly applied timolol in rabbits. Acta Ophthal-mologica 65: 63–66, 1987
Igarashi H, Sato Y, Hamada S, Kawasaki T. Studies on rabbit corneal permeability of local anaesthetics. Japanese Journal of Pharmacology 34: 429–434, 1984
Jones RF, Maurice DM, New methods of measuring the rate of aqueous flow in man with fluorescein. Experiemental Eye Research 5: 208–220. 1966
Kass MA. Topical carbonic anhydrase inhibitors. American Journal of Ophthalmology 107: 280–282. 1989
Kleinberg J, Dea FJ, Anderson JA, Leopold IH. Intraocular penetration of topically applied lincomycin hydrochloride in rabbits. Archives of Ophthalmology 97: 933–936. 1979
Korolkovas A. Essentials of medicinal chemistry. 2nd ed., pp. 92–97, J. Wiley and Sons, New York, 1988
Kumar V, Schoenwald RD, Barcellos WA, Chien DS, Folk JC. et al. Aqueous versus viscous phenylephrine I: systemic absorption and cardiovascular effects. Archives of Ophthalmology 104: 1189–1191. 1986
Lee DA, Brubaker RF. Effect of phenylephrine on aqueous humor flow. Current Eye Research 2: 89–92, 1982
Lee VHL, Chang SC, Oshiro CM, Smith RE. Ocular esterase composition in albino and pigmented rabbits: possible implications on ocular prodrug design and evaluation. Current Eye Research 4: 1117–1125, 1985
Lee VHL, Robinson JR. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. Journal of Pharmaceutical Sciences 68: 673–684, 1979
Lee VHL, Robinson JR. Disposition of pilocarpine in the pigmented rabbit eye. International Journal of Pharmaceutics 11: 155–165, 1982
Lee VHL, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. Journal of Ocular Pharmacology 2: 67–108. 1986
Leibowitz HM, Berrospi AR, Kupferman A, Restropo GV, Galvis V. et al. Penetration of topically administered prednisolone acetate into the human aqueous humor American. Journal of Ophthalmology 83: 402–406. 1977
Leibowitz HM, Ryan WJ, Kupferman A, DeSantis L. Bioavailability and corneal anti-inflammatory effect of topical suprofen. Investigative Ophthalmology and Visual Science 27: 628–631, 1986
Lewis RA, Schoenwald RD, Eller MG, Barfknecht CF. Phelps CD. Ethoxzolamide analogue gel. Archives of Ophthalmology 102: 1821–1823. 1984
Lynch MG, Brown RH, Goode SM, Schoenwald RD, Chien DS. Reduction of phenylephrine drop size in infants achieves equal dilation with decreased systemic absorption. Archives of Ophthalmology 105: 1364–1365. 1987
Makoid MC, Robinson JR. Pharmacokinetics of topically applied pilocarpine in albino rabbit eye. Journal of Pharmaceutical Sciences 68: 435–443. 1979
Makoid MC, Sieg JW, Robinson JR. Corneal drug absorption: an illustration of parallel first-order absorption and rapid loss of drug from absorption depot. Journal of Pharmaceutical Sciences 65: 150–152. 1976
Mandell AI, Stentz F, Kitabchi AE. Dipivalyl epinephrine: a new prodrug in the treatment of glaucoma. Ophthalmology 85: 268–275, 1978
Maren TH. Carbonic anhydrase: chemistry, physiology and inhibition. Physiological Review 47: 595–781, 1967
Maren TH, Jankowska L. Ocular pharmacology of sulfonamides: the cornea as barrier and depot. Current Eye Research 4: 399–408, 1985
Maren TH, Jankowska L, Sanyal G, Edelhauser H. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Experimental Eye Research 36: 457–480, 1983
Maren TH, Bar-Ilan A, Caster KC, Katritzky AR. Ocular pharmacology of methazolamide analogs: distribution in the eye and effects on pressure after topical application. Journal of Pharmacology and Experimental Therapeutics 241: 56–63, 1987
Maudgal PC, DeClerq E, Descamps J, Missotten L. Topical treatment of experimental herpes simplex keratouveitis with 2′-0-glycylacyclovir, a water soluble ester of acyclovir. Archives of Ophthalmology 102: 140–142. 1984
Maurice DM. Structures and fluids involved in the penetration of topically applied drugs. In Holly (Ed.) Clinical pharmacology of the anterior segment, pp. 7–20, Little. Brown and Co., Boston, 1980
Maurice DM. Kinetics of topically applied ophthalmic drugs. In Saettone et al. (Eds) Ophthalmic drug delivery: biopharmaceutical, technological and clinical aspects. Vol 11, pp. 19–26. Liviana Press, Springer-Verlag, Berlin, 1987
Maurice DM, Mishima S. Ocular Pharmacokinetics. In Sears (Ed.) Pharmacology of the eye, pp. 19–116, Springer-Verlag, Berlin, 1984
McDonald TO, Shadduck JA. Eye irritation. In Mailbach & Marzulli (Eds) Dermatotoxicology and Pharmacology, Vol. 4, pp. 139–191, J Wiley & Sons, New York, 1977
Mester U, Krasemann C, Werner H, Cefsulodin concentrations in rabbit eyes after intravenous and subconjunctival administration. Ophthalmic Research 14: 129–134, 1982
Michelson SR, Schwam H, Baldwin JJ, Mallorga GS, Ponticello RL, et al. Topically instilled MK-927: lack of correlation between corneal penetration rate constant and ocular hypotensive activity in rabbits. Investigative Ophthalmology and Visual Science (Suppl. 30): 37, 1989
Miller SC, Himmelstein KJ, Patton TF. A physiologically based pharmacokinetic model for the intraocular distribution of pilocarpine in rabbits. Journal of Pharmacokinetics and Biophar-maceutics 9: 653–677, 1981
Nagataki S, Mishima S. Pharmacokinetics of instilled drugs in the human eye. In Holly (Ed.) Clinical pharmacology of the anterior segment, pp. 33–49, Little, Brown and Co., Boston, 1980
Narurkar MM, Mitra AK. Physical chemical properties and corneal transport of a series of 5′-ester prodrugs of idoxuridine. Pharmaceutical Research (Suppl. 3): S-3, 48s, 1986
Notari RE, DeYoung JL, Reuning RH. Effect of parallel first-order drug loss from site of administration on calculated values for absorption rate constants. Journal of Pharmaceutical Sciences 61: 135–138, 1972
Occhipinti JR, Mosier MA, LaMotte J, Monji GT, Fluorophotometric measurement of human tear turnover rate. Current Eye Research 7: 995–1000, 1988
Palestine AG, Brubaker RF. Pharmacokinetics of fluorescein in the vitreous. Investigative Ophthalmology and Visual Science 21: 542–549, 1981
Patton TF, Robinson JR. Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes. Journal of Pharmaceutical Sciences 65: 1295–1301, 1976
Patton TF. Ocular drug disposition. In Robinson (Ed.) Ophthalmic drugs delivery systems, pp. 28–54. American Pharmaceutical Association, Washington, 1980
Petursson G, Cole R, Hanna C. Treatment of glaucoma using minidropsofclonidine. Archives of Ophthalmology 102: 1180–1181. 1984
Plazonnet B, Grove J, Durr M, Mazuel C, Quint M, Rozier A. Pharmacokinetics and biopharmaceutical aspects of some antiglaucoma drugs. In Saettone el al. (Eds) Ophthalmic drug delivery: biopharmaceutical, technological and clinical aspects. Vol 11, pp. 118–139, Liviana Press, Springer-Verlag, Berlin 1987
Ponticello GS, Freedman MB, Habecker CN, Lyle PA. Schwam H, et al. Thienothiopyran-2-sulfonamides: a novel class of water-soluble carbonic anhydrase inhibitors. Journal of Medicinal Chemistry 30: 591–597, 1987
Putnam ML, Schoenwald RD, Duffel MW, Barfknecht CF, Segarra TM, et al. Ocular disposition of aminozolamide in the rabbit eye. Investigative Ophthalmology and Visual Science 28: 1373–1382, 1987
Rootman DS, Jantzen JA, Gonzalez JR, Fischer MJ, Beuerman R, et al. Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit. Investigative Ophthalmology and Visual Science 29: 1397–1401. 1988
Rootman J, Ostry A, Gudauskas G. Pharmacokinetics and metabolism of 5-fluorouracil following subconjunctival verus intravenous administration. Canadian Journal of Ophthalmology 19: 187–191, 1984
Ryan SJ. Vision research: a national plan. 1987 evaluation and update, NIH Publication No. 87-2755, pp. 1–10, US Department of Health and Human Services, Bethesda, 1987
Schoenwald RD, Ward RL. Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. Journal of Pharmaceutical Sciences 67: 786–788, 1978
Schoenwald RD. The control of drug bioavailability from ophthalmic dosage forms. In Smolen & Ball (Eds) Controlled drug bioavailability, Vol. 3, pp. 257–306, J Wiley & Sons, New York, 1985
Schoenwald RD. The importance of optimizing corneal penetration. In Saettone et al (Eds) Ophthalmic drug delivery: biopharmaceutical, technological and clinical aspects, Vol 11, pp. 151–160, Liviana Press, Springer-Verlag, Berlin 1987
Schoenwald RD, Campbell D, Barfknecht C, Duffel M. Acetyl-ation of arylamines in ocular tissue homogenates of fast and slow acetylating rabbits. Investigative Ophthalmology and Visual Science 29: 438, 1988
Schoenwald RD, Chien DS. Ocular absorption and disposition of phenylephrine and phenylephnne oxazolidine. Biopharmaceu-tics and Drug Disposition 9: 527–538. 1988
Schoenwald RD, Folk JC, Kumar V, Piper JG. In vivo comparison of phenylephrine and phenylephrine oxazolidine instilled in the monkey eye. Journal of Ocular Pharmacology 3: 333–340, 1987a
Schoenwald RD, Harris RG, Turner D, Knowles W, Chien DS. Ophthalmic bioequivalence of steroid/antibiotic combination formulations. Biopharmaceutics and Drug Disposition 8: 527–548, 1987b
Schoenwald RD, Houseman JA. Disposition of cyclophos-phamide in the rabbit and human cornea. Biopharmaceutics and Drug Disposition 3: 231–241, 1982
Schoenwald RD, Huang HS. Corneal penetration behavior of beta-blocking agents I: physicochemical factors. Journal of Pharmaceutical Sciences 72: 1266–1272, 1983
Shell JW. Ophthalmic drug delivery systems. Drug Development Research 6: 245–261, 1985
Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Survey of Ophthalmology 26: 207–218, 1982
Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability. I. Evaluation of fluorometholone. Journal of Pharmaceutical Sciences 64: 931–936, 1975
Sieg JW, Robinson JR. Mechanistic studies on transcorneal permeation of fluorometholone. Journal of Pharmaceutical Sciences 70 1026–1029, 1981
Sugrue MF. Gauthcron P. Schmitt C. Viader MP. Conquet P. et al. On the pharmacology of L-645.151: a topically effectue ocular hypotensive carbonic anhydrase inhibitor. Journal of Pharmacology and Experimental Therapeutics 232: 534–540. 1985
Tang-Liu DDS. Liu SS. Weinkam RJ. Ocular and systemic bio-availability of ophthalmic flurbiprofen. Journal of Pharmacokinetics and Biopharmaceutics 12: 611–626. 1984
Tang-Liu DDS. Burke PJ. The effect of azone on ocular levo-bunolol absorption: calculating the area under the curve and its standard error using tissue sampling compartments. Pharmaceutical Research 5: 238–241. 1988
Taylor PB. Burd EM. Tabbara KF. Corneal and intraocular penetration of topical and subconjunctival fusidic acid. British Journal of Ophthalmology 71: 598–601. 1987
Wei CP. Anderson JA. Leopold I. Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephnne. Investigative Ophthalmology and Visual Sciences 17: 315–321. 1978
Ueno N. Refojo MF. Liu LHS. Pharmacokinetics of the antineoplastie agent 1.3-bis(2-chloroelhyl)-1-nitrosourea (BCNU) in the aqueous and vitreous of rabbit. Investigative Ophthalmology and Visual Science 23: 199–208. 1982
Valeri P. Palmen M. Severini G. Piccinelli D. Catanese B. Ocular pharmacokinenes of dapiprazole. Pharmacological Research Communications 18: 1093–1105. 1986
Walstad RA. Helium KB. Blika S. Dale LG. Fredrikson T. et al. Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humor, skin blister, cerebrospinal and pleural fluid. Journal of Antimicrobial Chemotherapy (Suppl. A. 12): 275-282. 1983
Wu WM. Hammer RH, Bodo N. Short-acting soft mydriatic agents. Pharmaceutical Research (Suppl. 5): S-99. 1988
Zigman S. Thotobiology of the lens. In Maisel (Ed.) Ocular lens, pp. 301–347. MarcelDekker. Inc., New York. 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schoenwald, R.D. Ocular Drug Delivery. Clin Pharmacokinet 18, 255–269 (1990). https://doi.org/10.2165/00003088-199018040-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199018040-00001